[Community pharmacists' interventions to prevent and screen chronic kidney disease patients]

Autor: Belaiche, Stéphanie, Mercier, Edwige, Cuny, Damien, Kambia, Nicolas, Wierre, Patrick, Bertoux, Elisabeth, Mascaut, Daniel, Azar, Raymond, Bataille, Pierre, Bourdon, Franck, Mac Namara, Evelyne, Maisonneuve, Nathalie, Painchart, Bernard, Vrigneau, Laurence, Noel, Christian, Decaudin, Bertrand, Glowacki, Francois
Přispěvatelé: Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 (GRITA), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Impact de l'environnement chimique sur la santé humaine - ULR 4483 (IMPECS), Université de Lille, Centre hospitalier [Valenciennes, Nord], Centre Hospitalier [Douai, Nord], Lille Inflammation Research International Center - U 995 (LIRIC), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)
Jazyk: francouzština
Rok vydání: 2016
Předmět:
Zdroj: Néphrologie & Thérapeutique
Néphrologie & Thérapeutique, 2017, Néphrologie et Thérapeutique, 13, pp.87-92. ⟨10.1016/j.nephro.2016.06.006⟩
ISSN: 1872-9177
1769-7255
DOI: 10.1016/j.nephro.2016.06.006⟩
Popis: International audience; Chronic kidney disease (CKD) is a major concern of public health. The pharmacist is known as a health practitioner involved in prevention and therapeutic education. Our study aimed at defining the impact of community pharmacists' interventions for preventing and screening CKD. In our observational prospective study of 5 months conducted in 109 community pharmacy, we included 2 groups of patients: A (therapeutic optimization): CKD patients and B (CKD screening): population at risk. In group A, we included 354 patients, mainly women (51.2%), in stage 3 of CKD, mean age 73 years old, with hypertension alone (40.6%) or associated with diabetes (44%). About 70% of the patients had a follow up by a nephrologist and 45% of them were good adherent according to the Morisky-Green self-report. However, approximately 20% of patients did not have nephroprotective treatments in their regimen although they were on stage 3 or 4 CKD patients, and about half of them were not aware of medical situations at risk. Concerning group B, 532 patients were included. The pharmaceutical interventions screened 10% of patients with a GFR
Databáze: OpenAIRE
Externí odkaz: